Chardan Capital Maintains Buy on Omega Therapeutics, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on Omega Therapeutics (NASDAQ:OMGA) but lowers the price target from $7 to $6.

August 07, 2024 | 10:49 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Chardan Capital analyst Keay Nakae maintains a Buy rating on Omega Therapeutics but lowers the price target from $7 to $6.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100